Oxford BioTherapeutics and Roche Collaborate to Discover Next-Gen Biologics for Cancer Treatment
Shots:
- Oxford has entered into a multi-year collaboration with Roche to identify antibody-based therapeutics in oncology, leveraging Oxford’s OGAP-Verify discovery platform
- As per the deal, Oxford will receive $36M upfront & over $1B in milestones, along with net sales-based royalties, while targets identified via OGAP-Verify will be validated through research collaboration, with Roche handling further research, development, & commercialization activities
- The OGAP-Verify discovery platform improves sensitivity, specificity, & reliability in identifying & validating human targets, with 3 programs (incl. OBT076 for advanced/refractory solid tumors) arising from OGAP, are in clinical development across the US & EU
Ref: Globenewswire | Image: Oxford & Roche
Related News:- Roche Reports the US FDA’s Approval of Susvimo to Treat Diabetic Macular Edema (DME)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
